Alexion Pharmaceuticals Price Target Raised to $181.00 at Barclays (ALXN)
Stock analysts at Barclays lifted their price objective on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $141.00 to $181.00 in a report issued on Friday, Analyst RN reports. The firm currently has an “overweight” rating on the stock. Barclays’ price target points to a potential upside of 14.03% from the company’s current price.
In other Alexion Pharmaceuticals news, EVP Stephen P. Squinto sold 1,118 shares of Alexion Pharmaceuticals stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $133.31, for a total value of $149,040.58. The sale was disclosed in a filing with the SEC, which is available at this link.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 2.02% during mid-day trading on Friday, hitting $158.73. 3,063,832 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a 1-year low of $81.82 and a 1-year high of $169.98. The stock has a 50-day moving average of $134.5 and a 200-day moving average of $119.3. The company has a market cap of $31.123 billion and a P/E ratio of 91.63.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, January 30th. The company reported $0.87 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. Analysts expect that Alexion Pharmaceuticals will post $3.60 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on ALXN. Analysts at Stifel Nicolaus raised their price target on shares of Alexion Pharmaceuticals from $138.00 to $207.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at Brean Capital raised their price target on shares of Alexion Pharmaceuticals from $142.00 to $200.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Finally, analysts at Nomura initiated coverage on shares of Alexion Pharmaceuticals in a research note to investors on Wednesday, January 8th. They set a “buy” rating and a $150.00 price target on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $149.28.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.